Cargando…

Local Treatment of Breast Cancer Liver Metastasis

Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been consid...

Descripción completa

Detalles Bibliográficos
Autores principales: Bale, Reto, Putzer, Daniel, Schullian, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770644/
https://www.ncbi.nlm.nih.gov/pubmed/31514362
http://dx.doi.org/10.3390/cancers11091341
_version_ 1783455524046503936
author Bale, Reto
Putzer, Daniel
Schullian, Peter
author_facet Bale, Reto
Putzer, Daniel
Schullian, Peter
author_sort Bale, Reto
collection PubMed
description Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been considered as the treatment standard despite a lack of robust evidence of benefit. However, due to the extent and location of disease and physical condition, the number of patients with BCLM who are eligible for surgery is limited. Palliative locoregional treatments of liver metastases (LM) include transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Percutaneous thermal ablation methods, such as radiofrequency ablation (RFA) and microwave ablation (MWA), are considered potentially curative local treatment options. They are less invasive, less expensive and have fewer contraindications and complication rates than surgery. Because conventional ultrasound- and computed tomography-guided single-probe thermal ablation is limited by tumor size, multi-probe stereotactic radiofrequency ablation (SRFA) with intraoperative image fusion for immediate, reliable judgment has been developed in order to treat large and multiple tumors within one session. This review focuses on the different minimally invasive local and locoregional treatment options for BCLM and attempts to describe their current and future role in the multidisciplinary treatment setting.
format Online
Article
Text
id pubmed-6770644
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67706442019-10-30 Local Treatment of Breast Cancer Liver Metastasis Bale, Reto Putzer, Daniel Schullian, Peter Cancers (Basel) Review Breast cancer represents a leading cause of death worldwide. Despite the advances in systemic therapies, the prognosis for patients with breast cancer liver metastasis (BCLM) remains poor. Especially in case of failure or cessation of systemic treatments, surgical resection for BCLMs has been considered as the treatment standard despite a lack of robust evidence of benefit. However, due to the extent and location of disease and physical condition, the number of patients with BCLM who are eligible for surgery is limited. Palliative locoregional treatments of liver metastases (LM) include transarterial embolization (TAE), transarterial chemoembolization (TACE), and selective internal radiotherapy (SIRT). Percutaneous thermal ablation methods, such as radiofrequency ablation (RFA) and microwave ablation (MWA), are considered potentially curative local treatment options. They are less invasive, less expensive and have fewer contraindications and complication rates than surgery. Because conventional ultrasound- and computed tomography-guided single-probe thermal ablation is limited by tumor size, multi-probe stereotactic radiofrequency ablation (SRFA) with intraoperative image fusion for immediate, reliable judgment has been developed in order to treat large and multiple tumors within one session. This review focuses on the different minimally invasive local and locoregional treatment options for BCLM and attempts to describe their current and future role in the multidisciplinary treatment setting. MDPI 2019-09-11 /pmc/articles/PMC6770644/ /pubmed/31514362 http://dx.doi.org/10.3390/cancers11091341 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bale, Reto
Putzer, Daniel
Schullian, Peter
Local Treatment of Breast Cancer Liver Metastasis
title Local Treatment of Breast Cancer Liver Metastasis
title_full Local Treatment of Breast Cancer Liver Metastasis
title_fullStr Local Treatment of Breast Cancer Liver Metastasis
title_full_unstemmed Local Treatment of Breast Cancer Liver Metastasis
title_short Local Treatment of Breast Cancer Liver Metastasis
title_sort local treatment of breast cancer liver metastasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770644/
https://www.ncbi.nlm.nih.gov/pubmed/31514362
http://dx.doi.org/10.3390/cancers11091341
work_keys_str_mv AT balereto localtreatmentofbreastcancerlivermetastasis
AT putzerdaniel localtreatmentofbreastcancerlivermetastasis
AT schullianpeter localtreatmentofbreastcancerlivermetastasis